Anaplastic Large Cell Lymphoma

Anaplastic large cell lymphoma is a cancer of T-cells, which are white blood cells that help your immune system fight germs. In ALCL, the cancer cells are large and strongly positive for a protein called CD30 when tested in the lab. Doctors group ALCL under “peripheral T-cell lymphomas,” which are uncommon compared with B-cell lymphomas. Some ALCLs have changes in a gene called ALK (anaplastic lymphoma kinase). These cases are called ALK-positive ALCL. Others lack ALK changes and are called ALK-negative ALCL. There are also forms that start in the skin and a special form that can occur around breast implants. Cancer.gov+1

Anaplastic large cell lymphoma (ALCL) is a cancer of mature T-cells (a type of white blood cell). The cancer cells are usually big and misshapen, and they strongly make a surface protein called CD30. Doctors recognize several forms: systemic ALK-positive ALCL (has an abnormal ALK protein, often from an ALK fusion like NPM1-ALK), systemic ALK-negative ALCL (no ALK protein, different genetics), primary cutaneous ALCL (starts in the skin), and breast-implant–associated ALCL (BIA-ALCL) (starts around textured breast implants). Most people feel painless swollen nodes or lumps; some have fever, weight loss, or night sweats. Diagnosis needs a biopsy, special stains (immunohistochemistry) showing strong CD30, and sometimes genetic tests. Staging and response checks use PET-CT. Treatment depends on the type and stage; for many adults with systemic disease, the modern first-line standard is brentuximab vedotin plus CHP (BV-CHP). Outcomes vary by subtype; ALK-positive disease usually does better than ALK-negative. (Key sources: Lymphoma+4NCBI+4PMC+4)

The exact cause is often unknown. In ALK-positive ALCL, the cancer is driven by an ALK fusion (commonly NPM1-ALK) that turns ALK on all the time, firing growth pathways, including STAT3. In ALK-negative ALCL, other genetic changes help drive the disease. Two important ones are DUSP22 rearrangements (some series suggest better outcomes) and TP63 rearrangements (generally worse outcomes). BIA-ALCL is linked to textured breast implants and long-standing inflammation around the implant capsule. (Key sources: Lippincott Journals+3PMC+3PMC+3)

Other names

Doctors and researchers may use different names for the same disease. You might see:

1. ALCL (short form).
2. CD30-positive large cell lymphoma (highlights the CD30 marker seen on the cancer cells).
3. Ki-1 lymphoma (an older name; Ki-1 was an early name for CD30).
4. ALK-positive ALCL and ALK-negative ALCL (based on ALK gene status).
5. Primary cutaneous ALCL (pcALCL) for disease that begins in the skin.
6. Breast implant–associated ALCL (BIA-ALCL) for the form that arises in the capsule or fluid around an implant. NCBI+2Cutaneous Lymphoma Foundation+2

Types of ALCL

Doctors separate ALCL into several types because they behave differently, need different tests, and can have different treatments and outlooks.

1. 1) Systemic ALK-positive ALCL.
   This type has a change (rearrangement) in the ALK gene—often a fusion called NPM1-ALK. It tends to affect children, teens, and younger adults more often than older adults, and it usually responds better to treatment than ALK-negative disease. The cells are CD30-positive. NCBI
2. 2) Systemic ALK-negative ALCL.
   This type does not have ALK rearrangements. It is more common in older adults. Some cases have other genetic changes such as DUSP22 or TP63 rearrangements, which can influence prognosis (outlook). All cases are CD30-positive. PMC+1
3. 3) Primary cutaneous ALCL (pcALCL).
   This form starts in the skin. It often shows up as one or more red, raised skin lumps or plaques that may ulcerate. It is part of the cutaneous CD30-positive lymphoproliferative disorders, which also include lymphomatoid papulosis (LyP). Skin-only disease usually has a more favorable course than systemic ALCL. Cutaneous Lymphoma Foundation+1
4. 4) Breast implant–associated ALCL (BIA-ALCL).
   This is a T-cell lymphoma that arises in the scar capsule or fluid around a breast implant. Most reported cases have involved textured implants rather than smooth ones. Cells are CD30-positive and ALK-negative. It usually presents as swelling (fluid/seroma), pain, or a mass near the implant years after surgery. U.S. Food and Drug Administration+1

Causes

For most people, no single cause is found. ALCL likely develops after a mix of genetic changes in T-cells plus immune or environmental triggers. Below are 20 factors known or suspected to play a role. Some apply to specific subtypes only.

1. ALK gene rearrangement (e.g., NPM1-ALK).
   This fusion drives ALK-positive ALCL by switching on growth signals. It is a disease-defining change, not something you inherit. NCBI

2. DUSP22 rearrangement (ALK-negative ALCL).
   DUSP22-rearranged cases were once thought to have an excellent outlook, but newer data suggest outcomes vary, showing this is a biologically distinct group. PMC+1

3. TP63 rearrangement (ALK-negative ALCL).
   This less common change is linked to more aggressive disease and a worse prognosis. PMC

4. Activation of the JAK/STAT pathway.
   Mutations that switch on STAT3 or JAK1 (especially in BIA-ALCL and some ALK-negative cases) can fuel cell growth and survival. MDPI

5. CD30 signaling.
   ALCL cells strongly express CD30, a surface protein linked to activation pathways that promote growth; this marker is central to diagnosis and targeted therapies. NCBI

6. Textured breast implants (BIA-ALCL).
   Most BIA-ALCL cases have been linked to textured implants. Long-standing inflammation in the capsule may contribute to cancer development. U.S. Food and Drug Administration+1

7. Chronic immune stimulation in the implant capsule (BIA-ALCL).
   Ongoing irritation, biofilm, or friction may keep the immune system activated for years, creating a setting where T-cells can become cancerous. PMC

8. Association with cutaneous CD30-positive disorders (pcALCL).
   pcALCL sits on a spectrum with lymphomatoid papulosis (LyP). Some patients move between these diagnoses over time, suggesting shared biology. PMC

9. Age.
   ALK-positive ALCL is more common in children and young adults, while ALK-negative ALCL is more frequent in older adults. Age shapes risk and outcomes but is not a direct “cause.” NCBI

10. Sex.
    ALCL overall shows a male predominance, especially ALK-positive systemic disease. NCBI

11. Immune dysregulation.
    Conditions that alter immune control may raise lymphoma risk in general; in ALCL, immune signaling pathways (like JAK/STAT) are commonly abnormal. MDPI

12. Genetic instability in T-cells.
    ALCL requires multiple DNA changes inside a single T-cell that allow unchecked growth; the exact triggers are not always known. (General concept summarized from classification reviews.) PMC

13. Extranodal inflammation.
    Some ALCLs start outside lymph nodes (skin, implant capsule). Local inflammation can be a long-term trigger for malignant change. PMC

14. Prior or concurrent cutaneous T-cell disease (pcALCL/LyP spectrum).
    People with LyP can later develop pcALCL (or vice versa), reflecting shared disease pathways rather than a simple cause-and-effect. AD Annals of Dermatology

15. Microenvironment and biofilms (BIA-ALCL).
    Bacterial biofilms on textured surfaces may sustain chronic immune activation that favors ALCL over time. PMC

16. Epigenetic changes.
    Changes in how genes are switched on/off (without changing DNA sequence) are described in cutaneous CD30-positive disorders and may help drive disease. Haematologica

17. Cytotoxic T-cell proteins.
    ALCL cells often produce proteins used by killer T-cells (e.g., TIA-1, granzyme B), which are part of their identity and may relate to how they grow and spread. NCBI

18. “Null-phenotype” (loss of usual T-cell markers).
    Some ALCLs lose common T-cell markers. This is a result of cancer biology, not a cause, but it shows the degree of immune-cell reprogramming. NCBI

19. Host factors and prognosis indices.
    Higher LDH, poor performance status, advanced stage, and multiple extranodal sites worsen outlook in aggressive lymphomas and help explain why some people fare worse. Cancer.gov

20. Chance.
    Even with known risks like textured implants, the absolute risk is low. Many people with implants never get BIA-ALCL. Many people without any known risk still develop ALCL, meaning chance and unknown factors remain important. U.S. Food and Drug Administration

Common symptoms and signs

Symptoms vary with the type and the body sites involved. Some people feel well for a long time. Others become sick quickly. See a doctor if you notice any of the following:

1. Painless swollen lymph nodes.
   Nodes in the neck, underarm, or groin may enlarge and stay enlarged. This is a typical first sign in systemic ALCL. Cancer.gov

2. “B-symptoms.”
   Unexplained fever, drenching night sweats, and weight loss are classic lymphoma symptoms. NCBI

3. General tiredness and weakness.
   This may reflect anemia, inflammation, or the body’s response to cancer.

4. Skin lumps or plaques (pcALCL).
   Red, raised, sometimes ulcerated skin lesions that do not go away. They may be single or multiple. Lymphoma Research Foundation

5. Itching or skin discomfort near lesions with pcALCL.

6. Breast swelling or sudden fluid collection (seroma) around an implant (BIA-ALCL).
   This often occurs years after implant placement. The breast may feel tight, swollen, or sore. U.S. Food and Drug Administration

7. A firm breast or chest wall mass (BIA-ALCL).
   Less commonly, a lump forms near the implant. U.S. Food and Drug Administration

8. Pain at the tumor site.
   Lymph nodes or masses can cause local pain or pressure.

9. Cough or shortness of breath.
   Chest nodes or fluid can irritate the lungs or airways.

10. Abdominal fullness or pain.
    The spleen or liver can enlarge in systemic disease. Cancer.gov

11. Unexplained rashes or new skin changes (pcALCL or systemic skin involvement).

12. Easy bruising or frequent infections.
    If the bone marrow is involved, you may have low blood counts.

13. Persistent fatigue with high LDH or inflammation markers on routine tests—often a clue that prompts deeper evaluation. Cancer.gov

14. Neurologic symptoms such as headache, confusion, numbness, or weakness if the nervous system is affected (uncommon but serious).

15. Unexplained, persistent swelling in one body area (e.g., arm or leg) from lymphatic blockage near bulky nodes.

How doctors diagnose ALCL

Doctors use a step-by-step approach. First, they listen to your story and examine you. Then, they order tests to confirm the diagnosis, classify the exact type, and stage the disease (find out where it is). No single test is enough by itself. The biopsy of a lymph node, skin lesion, capsule, or mass is the most important step because it allows pathologists to see the cells and do marker tests.

A) Physical examination

1) Full lymph-node and organ exam.
Your doctor feels the neck, armpits, and groin for enlarged nodes, and checks the abdomen for an enlarged liver or spleen. The size, number, and locations guide next steps. Cancer.gov

2) Skin examination.
For suspected pcALCL, the clinician looks for red or ulcerated plaques or nodules, measures them, and checks if there are multiple lesions or just one. Cutaneous Lymphoma Foundation

3) Breast and chest wall exam (if you have implants).
The doctor looks for swelling, fluid, or a mass near the implant and checks for tender areas. This helps decide if imaging or fluid sampling is needed. U.S. Food and Drug Administration

4) General check of performance status and B-symptoms.
Your overall fitness, fever, weight loss, and night sweats matter for staging and prognosis. Cancer.gov

B) Manual bedside maneuvers

5) Palpation of lymph nodes with attention to texture and mobility.
Hard, fixed clusters suggest cancer. Tender, soft nodes often suggest infection. This bedside information is not diagnostic but guides where to biopsy.

6) Abdominal palpation and percussion.
This looks for enlarged spleen or liver or dullness from fluid. Findings can point to internal involvement.

7) Bedside assessment for pleural or breast fluid.
In BIA-ALCL, a quick exam can suggest fluid around the implant. Ultrasound usually confirms it before fluid aspiration. U.S. Food and Drug Administration

C) Laboratory & pathological tests

8) Excisional or core biopsy of the most abnormal site.
This is the gold standard. The pathologist examines the tissue under the microscope and performs immunohistochemistry to show CD30 positivity and to check ALK status. Biopsy is essential to name the exact lymphoma. Cancer.gov

9) Immunohistochemistry panel (IHC).
Typical ALCL shows CD30-positive cells. ALK-positive cases stain for ALK. Many cases also show EMA and cytotoxic markers (e.g., TIA-1, granzyme B). These stains help confirm ALCL and separate it from look-alike diseases. NCBI

10) Flow cytometry (on tissue or fluid).
This test reads cell-surface markers on thousands of cells quickly. In BIA-ALCL, it may show CD30-positive, ALK-negative T-cells in implant fluid. GOV.UK

11) ALK testing (FISH, RT-PCR, or IHC).
These tests look for ALK gene breaks or fusions. A positive result classifies the lymphoma as ALK-positive ALCL, which carries different expectations and treatment choices. NCBI

12) DUSP22 and TP63 testing (FISH/NGS).
If ALK is negative, clinicians may test for DUSP22 or TP63 rearrangements because they have prognostic value and reflect different biology. PMC+1

13) Routine blood tests (CBC, chemistry, LDH).
A complete blood count checks for anemia or low white cells or platelets. LDH often rises with active lymphoma and helps with risk scoring. Cancer.gov

14) T-cell receptor (TCR) gene rearrangement studies (PCR/NGS).
These tests can show a clonal T-cell population, supporting the lymphoma diagnosis when morphology is tricky. (Referenced within PTCL diagnostic approaches.) Cancer.gov

D) Electrodiagnostic tests

These are not routine for every patient with ALCL. Doctors use them in selected situations to evaluate symptoms or to create a baseline before certain therapies.

15) Electrocardiogram (ECG).
If chemotherapy that can affect the heart is planned, or if you have chest symptoms, an ECG helps check heart rhythm and baseline status before treatment.

16) Nerve conduction studies and electromyography (EMG).
If you have numbness or weakness suggesting nerve injury (from disease or prior therapy), these tests measure nerve and muscle function to guide care.

17) Electroencephalogram (EEG).
If you have seizures or confusion and doctors suspect brain involvement, EEG helps evaluate electrical brain activity. (These uses are general to cancer care; they support, but do not replace, imaging and biopsy.)

E) Imaging tests

18) PET-CT scan (FDG-PET/CT).
This scan shows active lymphoma sites throughout the body and is widely used for initial staging and response assessment in NHL, including PTCL/ALCL. Cancer.gov

19) Contrast-enhanced CT or MRI of involved areas.
CT scans of the chest, abdomen, and pelvis are common in staging. MRI helps for brain, spine, or soft-tissue questions. Cancer.gov

20) Ultrasound of the breast/implant with fluid aspiration (BIA-ALCL).
Ultrasound can detect fluid around an implant and helps guide needle aspiration. The fluid is then tested by cytology, flow cytometry, and CD30 staining. U.S. Food and Drug Administration

Non-pharmacological treatments

Each item includes: 150-word description, purpose, and mechanism (in simple terms).

1) Patient education and shared decision-making

Description: Learning the exact subtype of ALCL, the stage, and the treatment plan helps people make informed choices. Education covers why CD30 and ALK matter, what a PET-CT does, and what “front-line” vs “salvage” therapy means. It also explains possible side effects (for example, nerve symptoms with some drugs), infection prevention, and when to call the clinic. Clear explanations reduce fear, improve treatment adherence, and help you plan work, school, fertility, and family support. Good education also includes written plans and reliable links so you do not have to remember everything during stressful visits. Many cancer centers use printed “teaching sheets,” videos, and nurse-led classes.
Purpose: Empower you to take part in decisions and follow treatment safely.
Mechanism: Understanding reduces uncertainty and improves adherence to complex cancer care. Cancer.gov

2) Multidisciplinary care and tumor board review

Description: A team (hematology/oncology, radiation oncology, pathology, radiology, surgery, plastic surgery for BIA-ALCL, dermatology for cutaneous ALCL, nursing, and supportive care) reviews your case together. They confirm the subtype, interpret scans, and align on best therapy (e.g., brentuximab vedotin + CHP for many CD30+ systemic cases; surgery for localized BIA-ALCL; skin-directed options for primary cutaneous ALCL).
Purpose: Reduce errors, ensure the plan fits your ALCL subtype, and time critical steps (biopsy, staging, treatment).
Mechanism: Team review applies current guidelines and evidence to your personal details. Annals of Oncology+1

3) Radiation therapy (when appropriate)

Description: Focused radiation can control pain or treat small, localized disease foci. It is commonly used for primary cutaneous ALCL lesions and for BIA-ALCL when residual disease persists after surgery or when margins are close; it may also be used palliatively for systemic ALCL to relieve symptoms from bulky nodes or bone lesions.
Purpose: Eradicate local lymphoma cells and reduce symptoms.
Mechanism: High-energy beams damage cancer DNA so cells stop dividing and die. PMC+1

4) Surgical excision for primary cutaneous ALCL lesions

Description: For single or few skin tumors in primary cutaneous ALCL, complete surgical removal is often curative. The surgery aims for clear margins while preserving function and appearance; sometimes small margins are acceptable with adjuvant radiation if needed.
Purpose: Remove all visible disease in the skin when it is limited.
Mechanism: Physical removal eliminates lymphoma cells from the lesion and reduces relapse risk in that spot. PMC

5) Complete capsulectomy and implant removal for BIA-ALCL

Description: When ALCL is confined to the breast implant capsule or a peri-implant fluid collection, the standard treatment is removing the implant and complete capsulectomy (removing the scar capsule). Surgeons send tissue and fluid for pathology, cytology, and CD30 testing. Early-stage BIA-ALCL without spread is often cured by surgery alone; more advanced disease may also need systemic therapy.
Purpose: Achieve complete local disease control and accurate staging.
Mechanism: Removing the entire capsule and implant eliminates the source and site where lymphoma cells are growing. Lippincott Journals+1

6) Physical therapy and safe exercise program

Description: Cancer fatigue, stiffness, and deconditioning are common during chemotherapy. A tailored plan focuses on gentle aerobic activity, mobility, and strength while protecting lines and avoiding infection risks in crowded gyms. Programs adjust intensity during neutropenia and post-transplant recovery.
Purpose: Reduce fatigue, preserve function, and improve quality of life.
Mechanism: Regular movement improves muscle efficiency, counters inflammation, and supports mood and sleep. Cancer.gov

7) Nutrition counseling (medical oncology dietitian)

Description: A dietitian helps you maintain weight, manage taste changes, mouth sores, nausea, constipation/diarrhea, and steroid-related appetite shifts. Guidance includes food safety during neutropenia, protein-rich meals, hydration, and folate/B12 support when pralatrexate is used (doctor-directed).
Purpose: Prevent malnutrition, support healing, and reduce treatment interruptions.
Mechanism: Adequate calories and protein maintain lean mass; micronutrient support can prevent specific drug-related deficiencies. ASH Publications

8) Infection-prevention coaching

Description: Hand hygiene, masking in high-risk settings during severe neutropenia, prompt fever reporting, safe food handling, oral care, and vaccination planning (e.g., inactivated vaccines at the right time after therapy or transplant) are taught. Live vaccines are avoided during intensive immunosuppression.
Purpose: Lower risk of serious infections during and after treatment.
Mechanism: Reduces exposure to pathogens and supports immune recovery. Cancer.gov

9) Psychosocial support and counseling

Description: Anxiety, low mood, and fear of recurrence are common. Psychologists, social workers, and peer groups offer coping tools, problem-solving for work/finances, and caregiver support. Early help can also improve adherence.
Purpose: Protect mental health and resilience through treatment.
Mechanism: Cognitive and behavioral strategies reduce distress and improve quality of life. Cancer.gov

10) Fertility preservation counseling (before treatment)

Description: Some ALCL treatments can affect fertility. Rapid referral for sperm banking or egg/embryo preservation is considered before starting chemotherapy when time allows; options depend on urgency and age.
Purpose: Preserve future family-building options.
Mechanism: Banking gametes or embryos before gonadotoxic therapy safeguards reproductive potential. Cancer.gov

11) Skin-directed therapies (for primary cutaneous ALCL)

Description: Besides surgery and radiation, localized intralesional corticosteroids or low-dose methotrexate may be used in select cases of primary cutaneous ALCL under specialist care. Decisions depend on lesion size, number, and cosmetic goals.
Purpose: Control skin-only disease while minimizing systemic side effects.
Mechanism: Local anti-inflammatory and anti-proliferative effects reduce tumor cells in the skin. ASH Publications

12) Pain management plan (non-opioid first)

Description: A layered plan may include acetaminophen, careful NSAID use (only if platelets and kidneys allow), topical agents, nerve-targeted medicines for neuropathic pain, and integrative options (heat/cold, relaxation). Opioids can be used short-term if needed.
Purpose: Keep pain controlled so you can move, sleep, and eat.
Mechanism: Multi-modal strategies target different pain pathways with fewer side effects than high-dose single agents. Cancer.gov

13) Mouth care and mucositis prevention

Description: Regular saline/baking soda rinses, soft toothbrushes, avoiding irritants, and clinic protocols (such as palifermin or cryotherapy with specific regimens) help prevent mouth sores that lead to weight loss and infection.
Purpose: Reduce mucositis risk and allow better oral intake.
Mechanism: Gentle cleansing and targeted agents protect and repair oral mucosa during chemotherapy. Cancer.gov

14) Sleep hygiene coaching

Description: Fixed sleep/wake times, limiting caffeine late in the day, light exposure in the morning, and screen limits at night help counter steroid-related insomnia and anxiety.
Purpose: Improve energy, mood, and immune recovery.
Mechanism: Better circadian alignment improves restorative sleep quality. Cancer.gov

15) Mind-body practices (mindfulness, breathing, yoga)

Description: Gentle, supervised yoga and mindfulness reduce stress and chemotherapy-related symptoms in many patients with cancer. Practices are adapted for central lines and balance issues.
Purpose: Improve coping, fatigue, and mood.
Mechanism: Lowers sympathetic arousal and inflammatory signaling, improving subjective well-being. Cancer.gov

16) Smoking cessation and alcohol moderation

Description: Quitting smoking and limiting alcohol support heart health (important during anthracycline therapy) and lower infection risk. Clinics can provide counseling and approved cessation aids.
Purpose: Reduce treatment complications and long-term health risks.
Mechanism: Removes ongoing toxin exposure that worsens vascular, heart, and immune function. Cancer.gov

17) Financial navigation and practical support

Description: Navigators help with insurance approvals (e.g., for brentuximab vedotin), transportation, lodging during radiation, and work leave paperwork.
Purpose: Prevent financial toxicity and treatment delays.
Mechanism: Early planning reduces missed doses and stress. Cancer.gov

18) Vaccination planning (timing and type)

Description: Your team times inactivated vaccines (e.g., influenza) appropriately and avoids live vaccines during active therapy or profound immunosuppression; post-transplant revaccination follows specific schedules.
Purpose: Reduce vaccine-preventable infections during recovery.
Mechanism: Optimizes immune response when safe and effective. Cancer.gov

19) Palliative care integration (any stage)

Description: Palliative care works alongside oncology to treat symptoms (pain, breathlessness, nausea), guide goals-of-care talks, and support families—not only at end of life.
Purpose: Improve quality of life throughout treatment.
Mechanism: Specialist symptom management plus communication support. Cancer.gov

20) Clinical trial consideration

Description: Trials can offer access to new targeted drugs (e.g., next-generation ALK inhibitors) or new combinations, especially in relapsed disease. Your team checks eligibility early so windows are not missed.
Purpose: Expand options and contribute to better future care.
Mechanism: Carefully monitored protocols test promising treatments compared with current standards. Cancer.gov+1

---

Drug treatments

Each item includes: ~150-word description + class, common dosage/time, purpose, mechanism, and key side effects. Doses are typical adult references; clinicians individualize for age, kidney/liver function, and regimen.

1) Brentuximab vedotin (BV)

Class: Anti-CD30 antibody-drug conjugate.
Dose/Time: Commonly 1.8 mg/kg IV day 1 of 21-day cycles when combined with CHP (“A+CHP”); number of cycles usually 6 (varies).
Purpose: First-line backbone for many CD30-positive PTCLs including systemic ALCL; also used in relapse.
Mechanism: BV binds CD30 on lymphoma cells and delivers monomethyl auristatin E (MMAE) to disrupt microtubules, causing cell death.
Key side effects: Peripheral neuropathy, neutropenia, infusion reactions; less alopecia than some chemo.
Evidence: The phase III ECHELON-2 trial showed A+CHP improved progression-free and overall survival versus CHOP in CD30+ PTCL, with the strongest benefit in systemic ALCL; 5-year results confirmed durable benefit. The Lancet+1

2) Cyclophosphamide (in CHOP/CHP)

Class: Alkylating agent.
Dose/Time: Often 750 mg/m² IV day 1 every 21 days as part of CHOP or A+CHP.
Purpose: Cytotoxic backbone in multi-drug regimens for systemic ALCL.
Mechanism: Cross-links DNA, stopping cancer cells from dividing.
Key side effects: Low blood counts, nausea, hair loss, cystitis (prevented with hydration), infertility risk.
Evidence: Standard in CHOP and maintained in A+CHP where vincristine is replaced by BV. PMC

3) Doxorubicin (in CHOP/CHP)

Class: Anthracycline.
Dose/Time: Often 50 mg/m² IV day 1 every 21 days in CHOP or A+CHP.
Purpose: Core cytotoxic for systemic ALCL.
Mechanism: Intercalates DNA and inhibits topoisomerase II.
Key side effects: Low counts, mouth sores, hair loss, cardiomyopathy risk (lifetime dose limits).
Evidence: CHOP/A+CHP remain standard first-line backbones for many PTCL including ALCL. PMC

4) Prednisone (in CHOP/CHP)

Class: Corticosteroid.
Dose/Time: Often 100 mg orally days 1–5 each 21-day cycle.
Purpose: Lymphotoxic effect and symptom relief (fever, swelling).
Mechanism: Triggers apoptosis in lymphoma cells and reduces inflammation.
Key side effects: High blood sugar, insomnia, mood changes, infection risk, appetite changes.
Evidence: Part of CHOP and A+CHP protocols. PMC

5) Vincristine (in CHOP; omitted in A+CHP)

Class: Vinca alkaloid (microtubule inhibitor).
Dose/Time: Often 1.4 mg/m² IV day 1 (max 2 mg) in CHOP.
Purpose: Legacy CHOP component; replaced by BV in A+CHP for CD30+ PTCL.
Mechanism: Inhibits microtubule assembly.
Key side effects: Peripheral neuropathy, constipation.
Evidence: A+CHP outperformed CHOP in ECHELON-2, largely by substituting BV for vincristine. The Lancet+1

6) Etoposide (CHOEP)

Class: Topoisomerase II inhibitor.
Dose/Time: Added to CHOP in some younger/fit patients (CHOEP).
Purpose: Intensifies first-line therapy in selected systemic ALCL cases.
Mechanism: Causes DNA breaks by stabilizing topoisomerase II complex.
Key side effects: Myelosuppression, mucositis, hair loss.
Evidence: Practice varies; guidelines discuss CHOEP for selected PTCL, but A+CHP is preferred in CD30+ disease. Annals of Oncology

7) Crizotinib (ALK inhibitor)

Class: Targeted tyrosine kinase inhibitor.
Dose/Time: Pediatric/young adult dosing per label; used mainly for relapsed/refractory ALK-positive systemic ALCL; adult use is off-label but supported by series.
Purpose: Target ALK-driven disease after relapse or when chemotherapy is unsuitable.
Mechanism: Blocks ALK signaling needed for tumor growth.
Key side effects: Visual disturbances, edema, liver enzyme elevation, GI upset.
Evidence: FDA approval (2021) for pediatric and young adult ALK-positive relapsed/refractory systemic ALCL based on Children’s Oncology Group results. U.S. Food and Drug Administration+1

8) Alectinib / Brigatinib / Lorlatinib (next-generation ALK inhibitors)

Class: Targeted ALK inhibitors.
Dose/Time: Regimens vary; mainly used off-label in relapsed ALK-positive ALCL when crizotinib fails or is not tolerated.
Purpose: Overcome resistance and achieve deeper remissions.
Mechanism: More potent ALK blockade and better CNS penetration (drug-specific).
Key side effects: Fatigue, liver tests changes; brigatinib may cause early pulmonary events; lorlatinib can affect lipids/CNS mood.
Evidence: Case series and expert guidance support consideration in trials or refractory cases. Annals of Oncology

9) Pralatrexate

Class: Antifolate chemotherapy.
Dose/Time: 30 mg/m² IV weekly for 6 of 7 weeks (with folic acid and vitamin B12 supplementation required).
Purpose: Relapsed/refractory PTCL including ALCL.
Mechanism: Enters cells via RFC-1 and inhibits dihydrofolate pathways, blocking DNA synthesis.
Key side effects: Mucositis (reduced by folate/B12), low counts, fatigue.
Evidence: Clinical activity shown across heavily pretreated PTCL; pooled analyses confirm responses. Nature+1

10) Romidepsin

Class: Histone deacetylase (HDAC) inhibitor.
Dose/Time: 14 mg/m² IV on days 1, 8, 15 of 28-day cycles (indication in PTCL was withdrawn in the US but remains referenced in guidelines as an option in some regions/contexts).
Purpose: Option in relapsed PTCL, sometimes in combination or trials.
Mechanism: Epigenetic modulation leads to tumor cell death.
Key side effects: Low counts, fatigue, nausea, ECG/QTc monitoring.
Evidence: Activity in PTCL; regulatory status varies; guidelines still discuss use depending on region and setting. PMC+1

11) Belinostat

Class: HDAC inhibitor.
Dose/Time: 1000 mg/m² IV daily on days 1–5 every 21 days.
Purpose: Relapsed/refractory PTCL including ALCL.
Mechanism: Epigenetic enzyme inhibition causing apoptosis.
Key side effects: Low counts, nausea, fatigue; monitor liver function.
Evidence: FDA-approved for R/R PTCL based on response data. AACR Journals

12) Brentuximab vedotin (monotherapy in relapse)

Class: Anti-CD30 ADC.
Dose/Time: Commonly 1.8 mg/kg IV every 3 weeks as single agent in relapsed CD30+ ALCL.
Purpose: Achieve remission with less multi-agent chemo toxicity.
Mechanism: Targeted cytotoxic delivery to CD30-positive cells.
Key side effects: Neuropathy, neutropenia, fatigue.
Evidence: Active in relapsed systemic and cutaneous CD30+ lymphomas; embedded in guidelines. Annals of Oncology

13) Gemcitabine-based regimens (e.g., Gemcitabine/Oxaliplatin or GDP)

Class: Cytotoxic combinations.
Dose/Time: Various salvage schedules.
Purpose: Second-line chemotherapy for relapsed PTCL/ALCL, sometimes as a bridge to transplant.
Mechanism: Interfere with DNA synthesis and repair.
Key side effects: Myelosuppression, neuropathy (oxaliplatin), GI upset.
Evidence: Included among accepted salvage options in guidelines. Annals of Oncology

14) ICE regimen (Ifosfamide/Carboplatin/Etoposide)

Class: Cytotoxic combination.
Dose/Time: Inpatient cycles every 21–28 days as salvage therapy.
Purpose: Cytoreduction before autologous stem cell transplant when chemosensitive.
Mechanism: DNA damage and apoptosis in rapidly dividing cells.
Key side effects: Low counts, nephrotoxicity (ifosfamide), neurotoxicity; requires close monitoring.
Evidence: Widely used salvage regimen in PTCL; guideline-listed. Annals of Oncology

15) Methotrexate (low-dose, cutaneous ALCL)

Class: Antimetabolite.
Dose/Time: Low weekly oral/SC doses in selected primary cutaneous ALCL under specialist care.
Purpose: Control limited skin disease or multiple lesions with less toxicity than systemic chemo.
Mechanism: Folate pathway inhibition slows lymphoma cell division.
Key side effects: Mouth sores, liver test elevation; folate supplementation is standard.
Evidence: Skin-directed systemic option in guidelines for CD30+ cutaneous LPDs. Medscape

16) Interferon-alpha (selected cutaneous cases)

Class: Immunomodulator.
Dose/Time: Subcutaneous dosing schedules vary; used less often now and mainly in specialized centers.
Purpose: Control stubborn skin disease when other options are unsuitable.
Mechanism: Immune activation and antiproliferative signals against tumor cells.
Key side effects: Flu-like symptoms, mood changes, cytopenias.
Evidence: Historical use and selected guideline mentions for cutaneous T-cell lymphomas. Medscape

17) Lenalidomide (off-label in PTCL)

Class: Immunomodulatory drug.
Dose/Time: Oral, days 1–21 of 28-day cycles; used off-label in relapsed PTCL/ALCL in trials or selected cases.
Purpose: Alternative in relapse for patients not fit for intensive chemo.
Mechanism: Modulates tumor microenvironment and T-cell function, anti-angiogenic effects.
Key side effects: Cytopenias, rash, thrombosis risk (consider prophylaxis).
Evidence: Small studies/series; consider only under expert guidance or trial. Annals of Oncology

18) Corticosteroids (dexamethasone/prednisone bursts)

Class: Glucocorticoids.
Dose/Time: Short bursts for symptom control or as part of salvage regimens.
Purpose: Rapidly shrink lymph nodes and improve symptoms before full therapy starts.
Mechanism: Lymphocyte apoptosis and anti-inflammatory effects.
Key side effects: Hyperglycemia, insomnia, infection risk.
Evidence: Standard supportive and cytoreductive role in lymphoma regimens. Cancer.gov

19) Autologous stem cell transplant (ASCT) – procedure with drug support

Class: Cellular therapy (requires high-dose chemo; supported by filgrastim/plerixafor to collect stem cells).
Dose/Time: Consider after good response to salvage therapy in relapsed chemosensitive ALCL.
Purpose: Prolong remission in selected patients.
Mechanism: High-dose chemo eradicates lymphoma; rescued by reinfusing your own stem cells.
Key side effects: Infection risk, mucositis, long recovery.
Evidence: Listed option for relapsed PTCL in guidelines. Cancer.gov

20) Allogeneic stem cell transplant (allo-SCT) – procedure

Class: Cellular therapy (donor cells).
Dose/Time: Consider in multiply relapsed or high-risk ALCL; decided case-by-case.
Purpose: Curative potential via graft-versus-lymphoma effect.
Mechanism: Donor immune system attacks residual lymphoma.
Key side effects: Graft-versus-host disease, infections.
Evidence: Considered for fit patients with refractory disease in specialist centers. Cancer.gov

---

Dietary molecular supplements

Important: Supplements do not treat ALCL. Always discuss with your oncologist because of drug interactions and infection risk. When pralatrexate is used, folic acid and vitamin B12 are not optional—they are required to reduce dangerous mouth sores.

1) Folic acid (required with pralatrexate)

Long description (≈150 words): Folic acid lowers the risk of severe mouth sores and some blood toxicities when taking pralatrexate. Typical practice is to start folic acid at least one week before the first pralatrexate dose and continue during treatment and for 30 days after the last dose. Doctors also give vitamin B12 injections on a schedule. Do not start folic acid on your own; your team sets the exact dose and timing to fit your regimen.
Dosage: Commonly 1 mg orally daily (doctor-directed).
Function: Replenishes folate pools to protect normal tissues from antifolate injury.
Mechanism: Counters off-target antifolate effects in non-cancer cells. Nature

2) Vitamin B12 (with pralatrexate)

Description: Given by injection (e.g., 1 mg IM every 8–10 weeks during treatment) to support red blood cell and mucosal health when using pralatrexate.
Dosage: Per oncology protocol.
Function: Prevents or reduces mucositis and anemia risk.
Mechanism: Restores cobalamin-dependent DNA synthesis in normal tissues. Nature

3) Vitamin D (if deficient)

Description: Many adults have low vitamin D; correcting deficiency supports bone health (important with steroids) and general wellness.
Dosage: As tested and prescribed (often 800–2000 IU/day or repletion plans).
Function: Bone and muscle support.
Mechanism: Restores vitamin D–dependent calcium metabolism; not anti-lymphoma therapy. Cancer.gov

4) Calcium (if low and on steroids)

Description: If your diet is low and you receive steroids, calcium with vitamin D may be advised to protect bone.
Dosage: Diet first; supplements only if recommended.
Function/Mechanism: Supports bone remodeling during steroid therapy. Cancer.gov

5) Oral nutrition supplements (medical shakes)

Description: Protein-calorie shakes can help maintain weight during nausea, taste change, or mucositis.
Dosage: As needed between meals.
Function: Prevents weight loss and treatment breaks.
Mechanism: Provides dense calories and protein when appetite is poor. Cancer.gov

6) Omega-3 fatty acids (cautious use)

Description: May help with appetite or fatigue for some people; bleeding risk exists with low platelets and interactions are possible.
Dosage: Only if cleared by oncology.
Function: General wellness; not disease-directed.
Mechanism: Anti-inflammatory effects on cell membranes. Cancer.gov

7) Zinc (short, low-dose if deficient)

Description: Zinc deficiency worsens taste alterations; brief, low-dose supplementation may help.
Dosage: Only after confirming need; high doses can cause copper deficiency.
Function: Taste support.
Mechanism: Cofactor in taste bud signaling and mucosal repair. Cancer.gov

8) Prophylactic probiotics – generally avoided during neutropenia

Description: Probiotics can cause bloodstream infections in immunocompromised patients; avoid unless your team explicitly recommends.
Dosage/Function/Mechanism: Not advised during neutropenia. Cancer.gov

9) Ginger (for mild nausea)

Description: Ginger tea/capsules may help mild nausea; do not replace antiemetic prescriptions.
Dosage: As advised by your team.
Function: Symptom relief.
Mechanism: Acts on GI receptors to reduce nausea sensation. Cancer.gov

10) Oral glutamine (mucositis support; mixed data)

Description: Some centers use glutamine swish-and-swallow for mouth soreness; evidence is mixed—ask your team.
Dosage: Clinic-directed only.
Function/Mechanism: May support mucosal cell repair during chemotherapy. Cancer.gov

---

Immunity-supporting / regenerative / stem-cell-related” drugs

There are no approved “stem-cell drugs” that cure ALCL. Instead, doctors use supportive biologic agents to protect the bone marrow or mobilize stem cells for transplant. These medicines should only be used under oncology guidance.

1) Filgrastim (G-CSF)

Description (~100 words): Stimulates white blood cell (neutrophil) production to shorten neutropenia after chemotherapy and before stem cell collection.
Dose: Daily SC injections per cycle or mobilization plan.
Function: Lowers infection risk and helps collect stem cells for ASCT.
Mechanism: Binds G-CSF receptors in marrow to boost neutrophil output. Cancer.gov

2) Pegfilgrastim (long-acting G-CSF)

Description: Single SC dose per cycle for febrile neutropenia prevention in regimens with significant risk.
Dose: Typically given 24 hours after chemo.
Function/Mechanism: Same as filgrastim with extended duration. Cancer.gov

3) Sargramostim (GM-CSF)

Description: Stimulates broader myeloid recovery in selected settings or trials.
Dose: SC/IV per protocol.
Function: Support marrow recovery.
Mechanism: GM-CSF receptor activation drives myeloid proliferation. Cancer.gov

4) Plerixafor (CXCR4 antagonist)

Description: Helps release stem cells from bone marrow into blood to collect for autologous transplant when G-CSF alone is insufficient.
Dose: SC before apheresis days.
Function: Improves stem cell yield.
Mechanism: Blocks CXCR4/SDF-1 axis causing stem cell egress. Cancer.gov

5) Epoetin alfa or darbepoetin (ESAs; select cases)

Description: May treat chemotherapy-related anemia when iron is adequate and transfusions are difficult; used cautiously due to clots/possible tumor effects.
Dose: SC per protocol; only when criteria met.
Function: Raise hemoglobin to reduce transfusions.
Mechanism: Stimulates red cell production in marrow. Cancer.gov

6) Intravenous immunoglobulin (IVIG; selected immunodeficiency)

Description: For patients with profound hypogammaglobulinemia and recurrent infections, IVIG may be considered. Not routine for all.
Dose: IV every 3–4 weeks as indicated.
Function: Replaces missing antibodies to prevent infections.
Mechanism: Provides pooled functional antibodies. Cancer.gov

---

Surgeries (procedures) and why they are done

1) Excisional lymph node or skin lesion biopsy

Procedure: Remove the whole node or skin tumor for full pathology and immunohistochemistry (CD30, ALK) and molecular tests.
Why: The only way to confirm the exact ALCL subtype and guide treatment. NCBI

2) Complete capsulectomy with implant removal (BIA-ALCL)

Procedure: Remove the implant and entire capsule; send tissue/fluid for CD30 testing and staging.
Why: Standard curative approach for localized BIA-ALCL; essential for accurate staging. Lippincott Journals+1

3) Surgical excision of solitary primary cutaneous ALCL lesion

Procedure: Remove the skin tumor with appropriate margins; reconstruct if needed.
Why: Often curative for single-site disease; may reduce need for radiation. PMC

4) Central venous port placement

Procedure: Implant a small port under the skin for repeated IV chemotherapy.
Why: Protects veins and allows safe delivery of vesicant drugs and long regimens. Cancer.gov

5) Splenectomy (rare, selected cases)

Procedure: Surgical removal of spleen.
Why: Considered only in special situations such as refractory cytopenias due to hypersplenism or diagnostic uncertainty—uncommon in ALCL. Cancer.gov

---

Prevention tips

1. Infection precautions: hand hygiene, mask in high-risk places during neutropenia, and call immediately for fever ≥38.0 °C. Cancer.gov

2. Food safety: avoid undercooked meats, unpasteurized products during neutropenia; wash produce well. Cancer.gov

3. Vaccination planning: take inactivated vaccines at safe times; avoid live vaccines during immunosuppression. Cancer.gov

4. Oral care: gentle brushing and saline/bicarbonate rinses to prevent mouth sores and infections. Cancer.gov

5. Protect the heart: report shortness of breath or swelling; keep blood pressure, diabetes, and lipids controlled—important with anthracyclines. Cancer.gov

6. Sun care for skin ALCL: protect treated skin to reduce irritation and secondary cancers. Medscape

7. Do not smoke; limit alcohol: improves healing and reduces complications. Cancer.gov

8. Stay active safely: light daily movement to fight fatigue and clots; follow PT guidance. Cancer.gov

9. Medication list: keep an updated list and check drug/herbal interactions (e.g., with targeted agents). Cancer.gov

10. Regular follow-up: attend all visits and scans as recommended by your center’s protocol. Annals of Oncology

---

When to see a doctor urgently

Call your oncology team immediately for fever ≥38.0 °C, uncontrolled vomiting/diarrhea, bleeding or bruising, new shortness of breath or chest pain, severe mouth sores preventing drinking, confusion, or rapidly enlarging lumps. During ALCL treatment, these signs may signal infection, blood count problems, blood clots, or treatment complications that need same-day care. If you have a breast implant and develop new swelling, a fluid collection, or a mass, seek urgent evaluation to rule out BIA-ALCL. Cancer.gov+1

---

What to eat” and “what to avoid

Eat: (a) small, frequent, high-protein meals (eggs, yogurt, fish, legumes), (b) soft foods if you have mouth sores (soups, smoothies), (c) plenty of fluids, (d) cooked vegetables and peeled fruits during severe neutropenia, and (e) calcium/vitamin D-rich foods if you use steroids. Avoid: (a) raw/undercooked meats or eggs and unpasteurized dairy during neutropenia, (b) alcohol excess (interacts with medicines and dehydrates), (c) high-dose unapproved supplements without oncology approval, (d) grapefruit with some targeted drugs if your team says so, and (e) herbal products that affect bleeding or the liver during chemotherapy. A dietitian can tailor an eating plan for you. Cancer.gov

---

Frequently asked questions

1) Is ALCL curable?
Many patients with systemic ALCL are cured, especially ALK-positive disease treated promptly with modern regimens like A+CHP. Primary cutaneous ALCL is often curable with local therapy. Outcomes vary by subtype, stage, and response to first-line therapy. PMC+1

2) What is the current standard first-line treatment for systemic ALCL?
For most CD30-positive cases (including systemic ALCL), brentuximab vedotin + CHP is preferred over CHOP based on the ECHELON-2 trial, which improved progression-free and overall survival. The Lancet+1

3) Do all patients get BV + CHP?
Not always. Choice depends on CD30 expression, age, fitness, comorbidities, and local guidelines. Your team individualizes the plan. Annals of Oncology

4) How is ALK-positive disease different?
ALK-positive ALCL tends to occur in younger patients and often has better outcomes. In relapse, ALK inhibitors like crizotinib may be used (pediatric/young adult approval). Nature+1

5) What scans do I need?
PET-CT is commonly used before and after treatment to stage disease and assess response; follow-up schedules vary. Cancer.gov

6) Is radiation still used?
Yes—particularly for primary cutaneous ALCL lesions, for selected bulky sites, or for residual localized disease after surgery in BIA-ALCL. PMC+1

7) What is BIA-ALCL and how is it treated?
A rare ALCL arising around certain textured breast implants. Many early cases are cured by implant removal and complete capsulectomy; advanced cases may need systemic therapy. Lippincott Journals+1

8) Will I need a transplant?
Some patients with relapsed, chemo-responsive ALCL are offered autologous transplant; allogeneic transplant is considered for multiply relapsed or refractory disease. Cancer.gov

9) Are there targeted pills for ALCL?
Yes, for ALK-positive disease in relapse (crizotinib; next-generation ALK inhibitors in trials). For CD30-positive disease, brentuximab vedotin is an antibody-drug conjugate (IV). U.S. Food and Drug Administration+1

10) What about romidepsin/belinostat/pralatrexate?
These are active in relapsed PTCL, including ALCL, used per regional availability and patient factors; pralatrexate needs folic acid and B12. ASH Publications+1

11) Are supplements helpful?
Supplements do not treat ALCL. Some (folate/B12) are required with pralatrexate; others are supportive only and must be cleared by your oncology team to avoid interactions. Nature

12) How is primary cutaneous ALCL different from systemic ALCL?
It mainly affects the skin and usually behaves more gently; many cases respond to surgery or radiation alone. Systemic ALCL involves nodes and organs and needs systemic therapy. PMC

13) Can ALCL come back?
Relapse can happen. Options include BV (if not previously used or as monotherapy), ALK inhibitors for ALK-positive disease, salvage chemotherapy, and transplant strategies. Annals of Oncology

14) What follow-up do I need?
Clinic visits and exams are scheduled regularly; imaging is tailored to symptoms and prior stage. Report new lumps, fevers, or unexplained weight loss promptly. Annals of Oncology

15) Where can I find trustworthy guidelines?
See the NCI PDQ pages for peripheral T-cell lymphomas and the ESMO-EHA Clinical Practice Guideline for T-/NK-cell lymphomas; for cutaneous disease, review NCCN/EORTC resources.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.